StemRx

What StemRx does

StemRx Bioscience Solutions Private Limited operates a regenerative medicine hospital and research platform headquartered in Navi Mumbai, India. Founded by Dr. Pradeep V. Mahajan in 2011 (with the hospital formally established in 2014), the company delivers autologous cell-based therapies — including Natural Killer (NK) cells, Mesenchymal Stem Cells (MSCs), and Lyophilized Platelet-Rich Plasma (L-PRP) — manufactured in its own GMP-grade laboratory under CDSCO and FDA clearances. The platform offers 52+ personalized protocols across 100+ degenerative conditions spanning neurological, orthopedic, metabolic, genetic, autoimmune, ophthalmology, oncology, and cosmetic indications, integrated with adjunct therapies such as Hyperbaric Oxygen Therapy (HBOT), Extracorporeal Blood Oxygenation and Ozonation (EBOO), and quantum energy modalities.

The business operates as a direct-to-patient specialty hospital network across five locations: three in India (Navi Mumbai, Mumbai, Hyderabad) and two international channel-partner centers (Accra, Ghana and Vacoas, Mauritius), with a wholly-owned presence in the Maldives. Revenue is generated through per-treatment professional services fees (quote-based and not publicly disclosed), supplemented by subsidized therapies under state health-scheme collaborations. Sub-brands StemRxIVF and StemRx Dental, a StemRx Bioscience e-commerce store, and an e-learning platform extend the commercial surface. The GTM model combines academic and research partnerships, webinars, SEO-optimized condition pages, and active earned media in major Indian publications to drive domestic and international patient acquisition. Ownership remains entirely with the founder; no institutional capital, no public listing, and a sub-50 headcount characterize the current operating footprint.

Name

StemRx

Legal name

StemRx Bioscience Solutions Private Limited

Website

https://stemrx.in

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

StemRx is a Mumbai-based regenerative medicine hospital that delivers autologous stem cell therapies and complementary treatments for 100+ degenerative conditions, serving patients directly through five centers across India, Ghana, and Mauritius.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cellular Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Regenerative medicine
• Cellular therapy
• Stem cell treatment
• Autologous cell therapy
• GMP biotherapeutics

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Regenerative Medicine / Cellular Therapy Services: StemRx generates revenue primarily through providing cellular therapy and regenerative medicine treatments to patients. The hospital delivers end-to-end healthcare — from consultation and evaluation through therapies, medication, and post-discharge strategies — under one roof. Treatments are personalized and protocol-based, serving patients across neurological, orthopedic, metabolic, genetic, autoimmune, and other conditions.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels8 records

Core offering

StemRx Bioscience Solutions is a hospital and research centre that delivers cellular therapy and regenerative medicine treatments using autologous (patient's own) stem cells — including Natural Killer (NK) Cells, Mesenchymal Stem Cells (MSCs), and Lyophilized Platelet-Rich Plasma (L-PRP) — through personalized protocols for 100+ degenerative conditions spanning neurological, orthopedic, autoimmune, metabolic, genetic, and ophthalmological disorders. The company operates a GMP-grade manufacturing laboratory and complements its core cellular therapy with Hyperbaric Oxygen Therapy (HBOT), Extracorporeal Blood Oxygenation and Ozonation (EBOO), Quantum Energy Medicine, Intestinal Microbiota Transfer, retrobulbar injections, and advanced rehabilitation, delivered across five centers in India, Ghana, and Mauritius.

Product overview

StemRx Hospital and Research Centre operates as a unified healthcare platform offering regenerative medicine treatments through multiple specialized centers. The core offering is Cellular Therapy and Regenerative Medicine using patient's own body cells (NK Cells, MSCs, L-PRP), supported by diagnostic Genetic Testing (450+ tests) and complementary therapies including Hyperbaric Oxygen Therapy, EBOO, and Quantum Energy Medicine. The organization provides specialized services through sub-brands including StemRxIVF for fertility, StemRx Dental for oral health, and maintains an Advanced Research Lab with GMP certification. The portfolio spans neurological (autism, cerebral palsy, Parkinson's), orthopedic (arthritis, AVN), metabolic, autoimmune, and genetic disorders, supported by an E-Learning platform and online store for bioscience products.

Differentiator

Problem solved

Functional benefit

Products and services

• StemRx Hospital and Research Centre Main healthcare facility providing regenerative medicine treatments for over 100+ degenerative conditions, combining cellular therapy, quantum energy medicine, and advanced rehabilitation protocols for individual patients.
• Cellular Therapy and Regenerative Medicine Cell-based therapy using patient's own body cells (NK Cells, MSCs, and L-PRP) for treatment of diseases, manufactured through a GMP grade laboratory.
• Hyperbaric Oxygen Therapy (HBOT) Treatment delivering pure oxygen in a pressurized chamber to enhance healing, reduce inflammation, stimulate regenerative medicines, and accelerate recovery.
• Extracorporeal Blood Oxygenation and Ozonation (EBOO) Blood purification therapy that enhances oxygenation, boosts immunity, and reduces inflammation through UV light exposure and ozone treatment.
• Quantum Energy Medicine Energy-based therapy including acupuncture, microcurrent therapy, and energy balancing to aid healing, reduce pain, and restore well-being.
• Genetic Testing DNA testing service offering 450+ tests to identify genetic conditions, root causes of health issues, and personalized lifestyle recommendations including diet adjustments.
• StemRxIVF Specialized IVF and fertility treatment clinic operating as part of the StemRx network, providing advanced infertility and reproductive healthcare.
• StemRx Dental Dental treatment services including cavities, gum care, tooth restoration, and smile correction, operating as a StemRx sub-brand.
• StemRx Store Online store for StemRx bioscience products and supplements.
• StemRx E-Learning Platform Online learning platform for professional education and training in regenerative medicine.

Quantifiable outcome

• 20,000+ patients treated with positive outcomes across 100+ conditions
• +4 more outcomes

Named customers7 records

Segments10 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Indiana School of MedicinecoreStrategic or Co-development PartnerDr. Mahajan serves as Adjunct Assistant Professor at Indiana School of Medicine. Collaboration involves regenerative medicine research, clinical trials, and academic exchange programs. Indiana University has collaborated with StemRx on research including the CliniMACS Prodigy Machine integration for hematological disorders.
• Ohio State UniversitycoreStrategic or Co-development PartnerDr. Mahajan received specialized training in regenerative medicine at Ohio State University in the USA. The institution has been involved in collaborative research and training that contributed to StemRx's clinical protocols.
• University of ViennaminorStrategic or Co-development PartnerDr. Mahajan holds a Diploma in Urology from the University of Vienna (1991) and has had teaching roles at the institution. Represents an academic training partnership.
• Fortis HospitalminorStrategic or Co-development PartnerDr. Mahajan serves as a Consulting Surgeon at Fortis Hospital and Seven Hills Hospital, facilitating referrals and collaborative patient care in the Mumbai region.
• Maharashtra University of Health Sciences (MUHS)minorStrategic or Co-development PartnerAcademic affiliation with MUHS for educational and research purposes in regenerative medicine.
• ITM (Institute of Tropical Medicine)minorStrategic or Co-development PartnerEducational role and collaboration with ITM for regenerative medicine research.
• Amity UniversityminorStrategic or Co-development PartnerAcademic involvement with Amity University for regenerative medicine education and research.
• Disha FoundationminorOthersNGO affiliation supporting community well-being through charitable healthcare initiatives.
• Siddhagiri Charitable TrustminorOthersNGO affiliation for charitable healthcare and community well-being.
• Medical Associations and ForumsminorOthersActive involvement in Medical Association Forums, The Rotary Club in Thane District, and Lions Club for professional networking and community health initiatives.
• Medivision Super Specialty Hospital (Hyderabad)coreChannel Partner/ Reseller/ DistributorMedivision Multispecialty Hospital in Hyderabad serves as StemRx's authorized center in Telangana, providing StemRx's regenerative treatments to South Indian patients under the StemRx brand.
• BMT Ghana & SCA FoundationcoreChannel Partner/ Reseller/ DistributorBMT Ghana & SCA Foundation operates StemRx's center at Greater Accra Hospital in Ghana, serving as the authorized partner for West Africa.
• Preventive Medicare Ltd. (Mauritius)coreChannel Partner/ Reseller/ DistributorPreventive Medicare Ltd. operates StemRx's Mauritius center at Vacoas, serving as the authorized partner for the Republic of Mauritius and Indian Ocean region.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Regional players

• Celltex Therapeutics: US-based adult mesenchymal stem cell therapy provider with GMP processing and a clinical services model. Comparable in business model (autologous stem cell therapy clinic + lab) but operates in the US rather than India.
• StemGenex: US stem cell treatment clinic focused on autologous therapies for degenerative conditions. Comparable as a direct-to-patient regenerative medicine clinic, but US-based with a different regulatory regime.

Broad incumbents

• Mesoblast: Global commercial-stage regenerative medicine company developing allogeneic cell therapies for inflammatory and degenerative diseases. Comparable in cellular therapy category, but a public listed developer rather than a clinical services provider.
• Reliance Life Sciences: Indian biotech arm of Reliance Group with regenerative medicine, biosimilars, and cell therapy programs including stem cell products. Comparable as an India-based large player with GMP cell therapy capabilities and broader portfolio.
• Athersys: US clinical-stage regenerative medicine company developing MultiStem cell therapy platform for multiple indications. Comparable as a stem cell therapy developer but operates through clinical trials rather than direct clinical services.

Direct peers

• Stempeutics Research: Bangalore-based stem cell therapy company (Manipal Group) developing pooled allogeneic MSC products and operating clinical trials in India. Directly comparable as an India-focused cell therapy developer/manufacturer targeting degenerative indications.
• Advancells: Indian stem cell therapy provider offering autologous and allogeneic stem cell treatments across multiple degenerative conditions, with NABL-accredited lab. Closely comparable business model delivering cell therapies direct-to-patient in India.
• ReeLabs: India-based stem cell therapy services company offering autologous treatments and processing services. Comparable as a domestic competitor in the Indian regenerative medicine clinic/services market.

Emerging players

• Pluristem Therapeutics: Clinical-stage developer of placenta-derived allogeneic cell therapies. Comparable as a cell therapy developer in regenerative medicine, but allogeneic rather than autologous and publicly traded.
• BrainStorm Cell Therapeutics: Clinical-stage developer of autologous cellular therapies for neurodegenerative diseases (ALS, MS). Comparable in autologous cell therapy category with overlapping neurological indication focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@stemrxindia/videos
• Instagraminstagram.com/stemrxindia
• Xx.com/StemRx_In
• Facebookfacebook.com/Stemmeticsindia
• LinkedInlinkedin.com/company/stemrxindia

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemRx